MRI in the assessment of putative treatments for multiple sclerosis

Imaging

Volumn 8, Issue 2, 1996, Pages 103-115

  Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BETA INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; GADOLINIUM; METHISOPRINOL; METHYLPREDNISOLONE; MITOXANTRONE; ROQUINIMEX;

ARTICLE; CONTRAST ENHANCEMENT; DISEASE COURSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0029783053     PISSN: 09656812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy: a practical guide. Drugs 1995; 49: 200-212.
2. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
3. Koopmans RA, Li DKB, Grochowski E et al. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989; 25: 74-81.
4. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988; 38: 1511-1515.
5. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-1094.
6. Thompson AJ, Kermode AG, Mac Manus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J 1990; 300: 631-634.
7. Barkhof F, Scheltens P, Frequin STFM et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determing disease activity. AJR 1992; 159: 1041-1047.
8. Harris JO, Frank JA, Patronas N, Mc Farlin DE, Mc Farland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-555.
9. Barkhof F, Tas MW, Frequin STFM et al. Limited duration of the effect of methylprednisolone on changes in MRI in multiple sclerosis. Neuroradiology 1994; 36: 382-387.
10. Miller DH, Thompson AJ, Morissey SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Pychiatry 1992; 55: 450-453.
11. Paty DW, Li DKB. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.
12. Miller DH, Barkhof F, Berry I et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683-688.
13. McFarland HF, Frank JA, Albert PS et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-766.
14. Miller DH, Barkhof F, Albert PS et al. Guidelines for the use of magnetic resonance techniques to monitor the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16.
15. Simon JH, Jacobs L, Cookfair D et al. The natural history of MS based on an annual MR snapshot results from the MSCRG study of intramuscular recombinant interferin beta-1a. Neurology 1995; 45(Suppl 4): A418.
16. Filippi M, Horsfield MA, Tofts PS et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995; 118: 1601-1612.
17. Stone LA, Frank JA, Albert PS et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-619.
18. Nauta JJP, Thompson AJ, Barkhof F et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994; 122: 6-14.
19. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
20. Carlo P, Koudriavtseva T, Gasperini C et al. The effect of fIFNβ-1a on monthly gadolinium-enhanced MRI and relapse rate in multiple sclerosis: results of 9-month treatment period. Neurology 1996; 46: A406.
21. Durelli L, Bongioanni MR, Cavallo R et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-413.
22. Bastianello S, Pozzili C, D'Andrea F et al. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994; 21: 266-270.
23. Krapf H, Mauch E, Fetzer U et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995; 37: 113-119.
24. Edan G. Demonstration of efficacy of mitoxantrone (MTX) using MRI in MS patients with very active disease. J Neuroimmunol 1995; Suppl 1: 16.
25. Moreau T, Thorpe J, Miller DH et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344: 298-301.
26. Sipe JC, Romine JS, Koziol JA et al. Cladrabine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
27. Karussis D, Meiner Z, Lehman D et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: Results of a double-blind placebo-controlled study with monthly MRI evaluation. Neurology 1995; 45(Suppl 4): A417.
28. Barkhof F, Thompson AJ, Hodgkinson S et al. Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS. J Neuroimmunol 1995; Suppl 1: 15.
29. Medaer R, Stinissen P, Truyen L et al. Depletion of myelin-basic-protein autoreactive T cells by T-cell vacination: pilot trial in multiple sclerosis. Lancet 1995; 346: 807-808.
30. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988; 15: 266-272.
31. Wiles CM, Omar L, Swan AV et al. Total lymphoid radiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57: 154-163.
32. Milligan NM, Miller DH, Compston DAS. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57: 164-168.
33. Smith ME, Stone LA, Albert PS et al. Clinical worsening in MS is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33: 480-489.
34. Khoury SJ, Guttmann CRG, Orav EJ et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burdon. Neurology 1994; 44: 2120-2124.
35. Filippi M, Paty DW, Kappos L et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45: 255-260.
36. Morissey SP, Miller DH, Kendall BE et al. Prognostic significance of brain MRI at presentation in patients with a clinically isokted syndrome suggestive of MS - a five year follow-up study. Brain 1993; 116: 115-146.
37. Youl BD, Turano G, Miller DH et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114: 2437-2450.
38. Truyen L, Gheuens J, van de Vyver FL et al. Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of an extensive standardized imaging protocol. J Neurol Sci 1990; 96: 173-182.
39. Koenig SH, Brown RD III, Spiller M et al. Relaxometry of brain: why white matter appears bright in MRI. Magn Reson Med 1990; 14: 482-495.
40. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.
41. Wolff SD, Balaban RS Magnetization transfer imaging: practical aspects and clinical applications. Radiology 1994; 192: 593-599.
42. Dousset V, Grossman RI, Ramer KN et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology 1992; 182: 483-491.
43. Dousset V, Brochet B, Vital A et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR 1995: 16: 225-231.
44. Gass A, Barker GJ, Kidd D et al. Correlation of magnetic transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36: 62-67.
45. Van Walderveen MAA, Barkhof F, Hommes OR et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: Relevance of hypointense lesions on short TR/short TE ("T1-weighted") spin-echo images. Neurology 1995; 45: 1684-1690.
46. Truyen L, van Waesberghe JHTM, van Walderveen MAA et al. Accumulation of hypointense lesions ("black holes") on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology in press.
47. Davie CA, Hawkins CP, Barker GJ et al. Serial proton magnetic resonance spectroscopy in multiple sclerosis. Brain 1994; 117: 49-58.
48. Davie CA, Barker GJ, Webb S et al. Proton magnetic resonance spectroscopy (MRS) study of cerebellar dysfunction in multiple sclerosis. Brain 1995; 118: 1583-1592.
49. Arnold DL, Matthews PM, Francis G et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14: 154-159.
50. Kidd D, Thorpe JW, Thompson AJ et al. Spinal cord MRI using multi-array coils and fast spin-echo. II. Findings in mutiple sclerosis. Neurology 1993; 43: 2632-2637.
51. Berry I, Manelfe C, Mueller E et al. Motor functional magnetic resonance imaging in multiple sclerosis. Neuroimmunology 1995; Suppl 1: 58.
52. Filippi M, Campi A, Martinelli V et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995; 59: 540-544.
53. Rydberg JN, Hammond CA, Grimm RC et al. Initial clinical experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequences. Radiology 1994; 193: 173-180.
54. Hashemi RH, Bradley WG, Chen DY et al. Suspected multiple sclerosis: MRI with a thin-section fast FLAIR pulse sequence. Radiology 1995; 196: 505-510.
55. Filippi M, Mammi S, Yousry T et al. Comparison of fast-FLAIR vs conventional SE sequences for measurement of brain MRI lesion load in patients with multiple sclerosis. J Neuroimmunol 1995; Suppl 1: 62.